SDC1 and plasma cell myeloma: As for the latter therapeutics, a major challenge ahead will be to identify molecular determinants (e.g., the heparanase/syndecan-1 axis in multiple myeloma) associated with a peculiar sensitivity to treatment, and to discover predictive biomarkers.